Olema Pharmaceuticals, Inc.
OLMANasdaq
$11.47
↑ +3.6%Jul 17 close · end-of-day
Price
1Y↑ +151.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.2B
Enterprise Value
$673.8M
P/E
—
P/S
—
P/B
2.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$185.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-38.5%
ROIC
—
Debt / Equity
—
Net Cash
$505.3M
Return 1Y
+154.3%
Company profile
Olema Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies for women's cancers. OP-1250, an estrogen receptor antagonist and a selective ER degrader, is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
- CEO
- Sean Bohen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 70
- Headquarters
- California
- Website
- olema.com
Management & directors
- Mitchell ShawnteCHIEF LEGAL OFFICER
- Austin Sasha LuVP of Finance and Controller
- Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.
- Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
- Bohen SeanPresident and CEO
- Zojwalla NaseemChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
OLMA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.52↑ +44.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$21.5M | -$71.5M | -$107.0M | -$105.0M | -$142.3M | -$178.7M |
| Net income | -$22.1M | -$71.1M | -$104.8M | -$96.7M | -$129.5M | -$162.5M |
| Diluted EPS | -$3.42 | -$1.80 | -$2.62 | -$2.14 | -$2.20 | -$1.87 |
| Operating cash flow | -$19.9M | -$50.7M | -$82.1M | -$83.7M | -$104.4M | -$146.7M |
| Free cash flow | -$19.9M | -$52.3M | -$82.4M | — | -$104.5M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$33.5M | -$37.6M | -$36.8M | -$34.9M | -$47.9M | -$45.9M | -$50.1M | -$58.0M |
| Net income | -$30.4M | -$34.6M | -$33.6M | -$30.4M | -$43.8M | -$42.2M | -$46.1M | -$53.1M |
| Diluted EPS | -$0.54 | -$0.60 | -$0.50 | -$0.36 | -$0.51 | -$0.49 | -$0.51 | -$0.52 |
| Operating cash flow | -$27.6M | -$27.0M | -$26.3M | -$44.0M | -$29.9M | -$34.5M | -$38.3M | -$46.0M |
| Free cash flow | -$27.6M | -$27.0M | -$26.3M | — | — | -$34.5M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-04 | Mitchell Shawnte· CHIEF LEGAL OFFICER | Sale | 24,767 | $24.25 | $600,599.75 | filing |
| 2026-03-04 | Mitchell Shawnte· CHIEF LEGAL OFFICER | Option exercise | 25,000 | $4.37 | $109,250.00 | filing |
| 2026-03-04 | Mitchell Shawnte· CHIEF LEGAL OFFICER | Sale | 233 | $24.69 | $5,752.77 | filing |
| 2026-03-03 | Mitchell Shawnte· CHIEF LEGAL OFFICER | Sale | 15,000 | $23.01 | $345,150.00 | filing |
| 2026-03-03 | Mitchell Shawnte· CHIEF LEGAL OFFICER | Option exercise | 15,000 | $4.37 | $65,550.00 | filing |
| 2026-02-02 | Austin Sasha Lu· VP of Finance and Controller | Award | 11,700 | $0.00 | $0.00 | filing |
| 2026-01-20 | Harmon Cyrus | Sale | 10,000 | $26.88 | $268,800.00 | filing |
| 2026-01-15 | Kovacs Shane William Charles· CH. OPERATING & FINANCIAL OFF. | Sale | 100,000 | $28.73 | $2.9M | filing |
| 2026-01-14 | Myles David C.· CH. DISCOV. & NON-CLIN DEV OFF | Sale | 35,003 | $28.99 | $1.0M | filing |
| 2026-01-14 | Myles David C.· CH. DISCOV. & NON-CLIN DEV OFF | Sale | 14,997 | $28.60 | $428,914.20 | filing |
| 2026-01-14 | Myles David C.· CH. DISCOV. & NON-CLIN DEV OFF | Option exercise | 50,000 | $4.87 | $243,500.00 | filing |
| 2026-01-14 | Harmon Cyrus | Sale | 3,489 | $29.12 | $101,599.68 | filing |
| 2026-01-13 | Myles David C.· CH. DISCOV. & NON-CLIN DEV OFF | Sale | 49,800 | $27.60 | $1.4M | filing |
| 2026-01-13 | Myles David C.· CH. DISCOV. & NON-CLIN DEV OFF | Option exercise | 50,000 | $4.87 | $243,500.00 | filing |
| 2026-01-13 | Kovacs Shane William Charles· CH. OPERATING & FINANCIAL OFF. | Sale | 3,822 | $28.01 | $107,054.22 | filing |
| 2026-01-13 | Myles David C.· CH. DISCOV. & NON-CLIN DEV OFF | Sale | 200 | $28.49 | $5,698.00 | filing |
| 2026-01-12 | Myles David C.· CH. DISCOV. & NON-CLIN DEV OFF | Sale | 10,000 | $28.34 | $283,400.00 | filing |
| 2025-12-26 | Bohen Sean· President and CEO | Gift | 8,500 | $0.00 | $0.00 | filing |
| 2025-12-23 | Zojwalla Naseem· Chief Medical Officer | Sale | 99,509 | $27.66 | $2.8M | filing |
| 2025-12-23 | Zojwalla Naseem· Chief Medical Officer | Option exercise | 50,000 | $7.02 | $351,000.00 | filing |
| 2025-12-22 | Zojwalla Naseem· Chief Medical Officer | Sale | 100,000 | $28.04 | $2.8M | filing |
| 2025-12-22 | Zojwalla Naseem· Chief Medical Officer | Option exercise | 42,818 | $15.25 | $652,974.50 | filing |
| 2025-12-22 | Harmon Cyrus | Sale | 2,881 | $28.53 | $82,194.93 | filing |
| 2025-12-22 | Zojwalla Naseem· Chief Medical Officer | Option exercise | 7,182 | $7.02 | $50,417.64 | filing |
| 2025-12-19 | CLARK IAN T | Sale | 193,056 | $29.71 | $5.7M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.